Virscio

Virscio is a US-based preclinical CRO founded in 2016 that provides specialized research services to biopharma clients, with a core focus on advanced nonhuman primate models for infectious diseases and drug delivery. The company positions itself as a partner to de-risk therapeutic programs prior to human trials by applying optimized, humane NHP models and endpoints. Its value proposition centers on improving R&D efficiency and clinical translatability through its integrated capabilities, scientific expertise, and commitment to innovation in preclinical science. Virscio operates as a service provider, not a therapeutic developer, generating revenue through collaborative and contract research engagements.

Integrated preclinical platform specializing in the development, optimization, and humane application of advanced nonhuman primate (NHP) translational models and endpoints. Focus on multidisciplinary science, best methods, and collaborative engagement to improve the prediction of clinical outcomes for drug delivery and infectious disease research.

Virscio competes in the niche segment of nonhuman primate-focused preclinical CROs against other specialized providers and the large, full-service CROs (e.g., Charles River Laboratories, Labcorp) that also offer NHP capabilities. Its differentiation is its focused translational expertise, integrated multidisciplinary approach, and stated commitment to innovation and model optimization within the NHP space.